Pimicotinib FDA Approval: What Pimjetmi Means for TGCT
- 6 views
- 0 likes
- 0 comments
- All languages combined

Sign in and earn +30 points by reading this
Read to the end, wait a few seconds, then tap the claim button below.
In short
As of 13 November 2026, the US FDA has approved pimicotinib (Pimjetmi), a once-daily oral CSF-1R inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) when surgery may worsen function or cause severe harm [1]. In the MANEUVER trial, 56% responded versus 3.2% on placebo [1].
Key takeaways
- The FDA approved pimicotinib (Pimjetmi, EMD Serono) on 10 November 2026 for adults with symptomatic TGCT for whom surgery may cause worsening functional limitation or severe morbidity [1].
- In the MANEUVER trial, the overall response rate at week 25 was 56% with pimicotinib and 3.2% with placebo, according to the FDA [1].
- Patients on pimicotinib also gained joint range of motion, had less worst pain and better physical function than those on placebo [1].
- Common side effects include itching, rash, facial and eye-area swelling, fatigue, nausea and headache; the label warns about liver toxicity and harm to an unborn baby [1].
- The drug was developed by Abbisko Therapeutics; Merck KGaA, Darmstadt, Germany holds worldwide commercial rights [3][6].
- It was already approved in China (December 2025), Canada (June 2026) and Switzerland (October 2026), according to the companies [3][6].
On this page 11 sections
- What is tenosynovial giant cell tumor (TGCT)?
- How is TGCT diagnosed and treated?
- Who is Pimjetmi approved for?
- What did the MANEUVER trial show?
- What are the side effects of pimicotinib?
- Where else is pimicotinib approved?
- What comes next for TGCT treatment?
- Common mistakes
- Frequently asked questions
- Glossary
- Sources
What is tenosynovial giant cell tumor (TGCT)?
TGCT is a rare, usually non-cancerous tumour in which the lining of joints, bursae or tendon sheaths thickens and overgrows; it does not spread to other parts of the body but can damage the affected joint [4][5].
- Symptoms: pain, swelling, tenderness, warmth and limited movement, and sometimes locking of the joint [4][5].
- Two types: localised TGCT tends to affect smaller joints such as fingers and parts of the foot; diffuse TGCT affects large joints, most often the knee [5].
- Old name: diffuse TGCT was previously called pigmented villonodular synovitis (PVNS) [5].
- Who gets it: NORD says it mainly affects people aged 25 to 50, with a median age at diagnosis of 40 [5].
- How rare: NORD cites a 2017 Dutch study estimating 43 new cases per million people a year [5].
- Cause: NIH's Genetic and Rare Diseases Information Center says the cause is unknown [4].
Surgery is often the first treatment, but tumours can come back, particularly the diffuse type, and repeated recurrence can damage the joint and, in rare cases, lead to amputation, NORD says [5].
EMD Serono, which markets the drug in the US, says up to half of people with TGCT may be misdiagnosed at first, citing a patient registry study [3].
How is TGCT diagnosed and treated?
NORD says MRI is the preferred way to detect and characterise TGCT, and surgery to remove the affected joint lining is often the first treatment, though there is no consensus on the standard of care [5].
- Diagnostic delay: early symptoms are often vague, and there is usually a delay of 3 to 4 years on average from first symptoms to diagnosis [5].
- Imaging: X-rays can show bone or cartilage damage but do not establish the diagnosis; MRI can show iron-containing deposits called haemosiderin that point to TGCT [5].
- Biopsy: sometimes a tissue sample is needed to confirm the diagnosis, although many patients are diagnosed with MRI alone [5].
- Surgery: synovectomy removes the affected joint lining, by open or arthroscopic surgery; no randomised studies have compared the two [5].
- Recurrence: NORD gives a recurrence risk of about 10% to 15% after surgery for localised TGCT, and about 50% to 70% for diffuse TGCT [5].
- Expert centres: NORD cites one nationwide study in which recurrence was 42% for patients first treated at an expert centre versus 92% at community centres [5].
This is the context for the FDA's narrow label: pimicotinib is approved for patients in whom surgery may worsen function or cause severe morbidity [1].
Who is Pimjetmi approved for?
The FDA approved pimicotinib for adults with symptomatic TGCT when "surgical resection may cause worsening functional limitation or severe morbidity" [1].
- Adults only: the company's safety information says it is not known whether the drug is safe and effective in children [3].
- Oral, once daily: it is taken by mouth once a day; the FDA classifies it as a kinase inhibitor [1][3].
- How it works: it blocks the colony-stimulating factor-1 receptor (CSF-1R), according to the trial paper and the company [2][3].
- Expedited review: it received fast track and breakthrough therapy designation [1].
- International review: the FDA reviewed it under Project Orbis with regulators in Australia, Canada, Israel, Switzerland and the UK, with the European Medicines Agency as an observer [1].
The FDA says full prescribing information will be posted on Drugs@FDA [1]. The approval holder named by the FDA is EMD Serono, Inc. [1].
What did the MANEUVER trial show?
In MANEUVER, 94 patients were randomly assigned 2:1 to pimicotinib or placebo for 24 weeks; at week 25, tumours had shrunk enough to count as a response in 56% on pimicotinib versus 3.2% on placebo, according to the FDA [1][2].
- Design: double-blind, placebo-controlled, at 40 specialised hospitals in Asia, Europe and North America [2].
- Patients: 63 on pimicotinib and 31 on placebo; 45 from China and 49 from elsewhere; 68% were female [2].
- Response in the Lancet paper: 54% (34 of 63) versus 3% (1 of 31), an absolute difference of 51% [2]. The FDA's figure is 56% (95% CI 42 to 68) [1].
- Durability: median duration of response was not reached; 91% of responders had a response lasting at least 6 months and 77% at least 12 months [1].
- Function and pain: statistically significant gains in active range of motion, reduced worst pain and better physical function scores at week 25 [1].
- Early effect: the company says 41.3% had responded by week 13 [3].
Response was measured by blinded independent central review using RECIST v1.1, a standard way of measuring tumour size on scans [1][2]. The trial was funded by Abbisko Therapeutics [2].
The table below sets out the main results.
What are the side effects of pimicotinib?
The FDA lists pruritus (itching), rash, facial swelling, swelling around the eyes, fatigue, nausea, headache and peripheral oedema as the most common side effects, each in more than 20% of patients [1].
- Lab changes: the most common abnormalities (over 30%) were raised creatine phosphokinase, lactate dehydrogenase, liver enzymes (AST, ALT), lipase, amylase and cholesterol [1].
- Warnings: the label includes warnings for liver toxicity, harm to an unborn baby, and raised serum creatinine without affecting kidney function [1].
- Liver monitoring: the company's safety information says blood tests are done before treatment, monthly for 3 months, then every 3 months for the rest of the first year [3].
- Pregnancy: the company says effective contraception is needed during treatment and for 2 weeks after the last dose, for women who can become pregnant and for men with such partners [3].
- Stopping treatment: in the trial, one patient (2%) stopped because of side effects and five (8%) had dose reductions [2].
- Severe events: the only grade 3 or 4 event in more than 10% was a rise in creatine phosphokinase, in 13% [2].
The Lancet paper reports no cholestatic liver damage, drug-induced liver injury or loss of skin or hair colour during the trial [2].
This is not medical advice. Decisions about your own treatment belong with a qualified clinician who knows your history.
Where else is pimicotinib approved?
Before the US decision, pimicotinib was approved in China in December 2025, in Canada in June 2026 and in Switzerland in October 2026, according to Abbisko and EMD Serono [3][6].
- Europe: it has PRIME (priority medicine) designation from the European Medicines Agency, but no EU approval has been announced [3].
- Other Orbis partners: the FDA lists Australia, Israel and the UK among its Orbis partners and says other applications may still be under review [1].
- Rights: Abbisko developed the drug and licensed worldwide commercial rights to Merck KGaA, Darmstadt, Germany [6].
- Milestone: Abbisko says it will receive an additional milestone payment on the first US commercial sale and is eligible for royalties [6].
Danny Bar-Zohar, CEO Healthcare at Merck KGaA, said the approval brings "real hope to patients and their families" [3]. That statement comes from the manufacturer [3].
What comes next for TGCT treatment?
MANEUVER continues beyond the 24-week placebo-controlled part, with later open-label parts, and the company has reported longer follow-up [2][3].
- Longer follow-up: the company says 77% of week-25 responders kept their benefit after a further 12 months, with a median follow-up of 14.3 months [3].
- Prescribing details: the FDA said the full US label would be posted on Drugs@FDA [1].
- Patient support: Sydney Stern of TGCT Support (Life Raft Group) said patients not likely to benefit from surgery alone still need treatments that are tolerable and improve pain and function [3].
Rare-disease drug names are easy for search tools and chatbots to confuse; why AI answers can mix up drugs is explained in AI Hallucinations Explained: Why Chatbots Make Things Up and How to Get Accurate Answers. What AI tools can and cannot do in health care is covered in AI in Healthcare: What It Can Do Today, Where It Fails and How It Is Regulated.
Common mistakes
Calling TGCT a cancer that spreads
Fix: NORD says TGCT is benign and does not metastasise [5].
Thinking every TGCT patient qualifies
Fix: Approval covers adults where surgery may worsen function or cause severe harm [1].
Ignoring liver monitoring
Fix: The label warns of liver toxicity and requires blood tests [1][3].
Assuming EU approval
Fix: The EMA has given PRIME status only; no EU approval is announced [3].
Mixing up 54% and 56%
Frequently asked questions
What is tenosynovial giant cell tumor (TGCT)?
A rare, usually benign tumour of the joint or tendon lining that can damage the joint [4][5].
How is TGCT diagnosed and treated?
Usually by MRI, with surgery often first; recurrence is common in diffuse TGCT [5].
Who is Pimjetmi approved for?
Adults with symptomatic TGCT where surgery may worsen function or cause severe harm [1].
What did the MANEUVER trial show?
56% responded on pimicotinib versus 3.2% on placebo at week 25 [1].
What are the side effects of pimicotinib?
Itching, rash, facial swelling, fatigue; warnings for liver toxicity and pregnancy harm [1].
Glossary
- TGCT
- Tenosynovial giant cell tumor, a rare tumour of the joint or tendon lining.
- CSF-1R inhibitor
- A drug that blocks the colony-stimulating factor-1 receptor.
- Synovium
- The thin membrane lining joints, bursae and tendon sheaths.
- Overall response rate
- The share of patients whose tumours shrink by a set amount on scans.
- RECIST
- Standard criteria for measuring tumour response on imaging.
- Project Orbis
- An FDA framework for reviewing cancer drugs alongside other regulators.
Sources
- FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor US Food and Drug Administration · 2026-11-10
- Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER) The Lancet · 2026-03-05
- FDA Approves PIMJETMI (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor EMD Serono · 2026-11-10
- Tenosynovial giant cell tumor, diffuse type NIH Genetic and Rare Diseases Information Center
- Tenosynovial Giant Cell Tumor National Organization for Rare Disorders · 2023-09-29
- PIMJETMI (pimicotinib) receives U.S. FDA approval for TGCT Abbisko Therapeutics (PR Newswire) · 2026-11-10
Comments
Top comments